Shuko Harada

University of Alabama at Birmingham

H指数:26

被引数:2,823

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hybrid/collision ameloblastoma-ameloblastic fibroma: a case with molecular features supporting a tumor-in-tumor model

杂交/碰撞型成釉细胞瘤-成釉细胞纤维瘤：一例支持肿瘤中肿瘤模型的分子特征

Virchows Archiv

IF3.1

2026-09-250

Revisiting HER2-negative breast cancer in the era of HER2-low and HER2-ultralow expression: Assessment of interobserver variability

在HER2低表达和HER2超低表达时代重新审视HER2阴性乳腺癌：评估观察者间变异性

Breast

IF7.9

2026-08-180

OAAI

MPRIP::PDGFRB fusion identified in a male patient with a myeloid/lymphoid neoplasm with eosinophilia

MPRIP::PDGFRB融合在伴嗜酸性粒细胞增多症的髓系/淋巴系肿瘤男性患者中的鉴定

Annals of Hematology

IF2.4

2026-04-270

OAAI

Systemic Xanthogranuloma or Erdheim-Chester disease: A systematic review re-examining the classification challenge

系统性黄色肉芽肿或Erdheim-Chester病：一项重新审视分类挑战的系统综述

British Journal of Haematology

IF3.8

2026-02-010

PRE

Primary Ewing Sarcoma of the Kidney

肾原发性尤因肉瘤：包括罕见EWSR1::ETV4融合的24例患者临床病理及分子学研究

AMERICAN JOURNAL OF SURGICAL PATHOLOGY

IF4.2

2025-10-010

PRE

Association between p16INK4A expression and a treatment response to CDK4/6 inhibitor in advanced breast carcinoma

p16INK4A表达与CDK4/6抑制剂治疗反应在晚期乳腺癌中的关联

Human Pathology

IF2.6

2025-08-070

PRE

A Genomic Alteration in GATA3 Affects Treatment Responses with a CDK4/6 Inhibitor Collaborating with p18INK4C Expression in Advanced Breast Carcinoma

GATA3基因的基因组改变影响CDK4/6抑制剂的治疗反应，并与p18INK4C表达协同作用，影响晚期乳腺癌的治疗效果。

Modern Pathology

IF5.5

2025-07-160

PRE

SFPQ::TFE3-rearranged PEComa: Differences and analogies with renal cell carcinoma carrying the same translocation

SFPQ::TFE3-重排的PEComa：与携带相同易位的肾细胞癌的差异与相似之处

PATHOLOGY RESEARCH AND PRACTICE

IF3.2

2025-06-010

OAAI

Hepatic adenomas in males: Is molecular characterization helpful in guiding its management?

男性肝腺瘤：分子特征分析对其管理指导是否有帮助？

HUMAN PATHOLOGY

IF2.6

2025-05-010

PRE

Association between p16/INK4A Expression and a Treatment Response with a CDK4/6 Inhibitor in Advanced Breast Carcinoma

LABORATORY INVESTIGATION

IF4.2

2025-03-010

PRE

A Truncating Mutation of the GATA3 Gene Affects the Treatment Response with a CDK4/6 Inhibitor via p18/INK4C Expression in Advanced Breast Carcinoma

LABORATORY INVESTIGATION

IF4.2

2025-03-010

PRE

Clinicopathological and Molecular Characterization of DNA Mismatch Repair Deficient Endometrial Carcinomas

LABORATORY INVESTIGATION

IF4.2

2025-03-010

PRE

mascRNA directs nutrient-insensitive activation of the LARS-mTOR pathway in breast cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2024-11-140

PRE

p53 protein expression patterns associated with TP53 mutations in breast carcinoma

乳腺癌中TP53突变相关的p53蛋白表达模式

BREAST CANCER RESEARCH AND TREATMENT

IF3

2024-06-200

OAAI

Molecular Characterization of Juxtaglomerular Cell Tumors: Evidence of Alterations in MAPK-RAS Pathway

肾小球细胞瘤的分子特征: mapk-ras通路改变的证据

MODERN PATHOLOGY

IF5.5

2024-06-012

PRE

Non-small cell lung carcinoma with clear cell features: a clinicopathologic, immunohistochemical, and molecular study of 31 cases

VIRCHOWS ARCHIV

IF3.1

2024-05-301

PRE

Navigating NextGeneration Sequencing Laboratory Developed Tests: A Critical Look at Proficiency Testing, US Food and Drug Administration Regulations, and Clinical Laboratory Performance Tests Reply

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

IF3.2

2024-04-250

Nested and Large Nested Subtypes of Urothelial Carcinoma of the Upper Urinary Tract: A Multi-institutional Study

MODERN PATHOLOGY

IF5.5

2023-12-012

PRE

Navigating Next-Generation Sequencing Laboratory Developed Tests A Critical Look at Proficiency Testing, US Food and Drug Administration Regulations, and Clinical Laboratory Performance

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

IF3.2

2023-11-072

De-differentiated liposarcomas with solitary fibrous tumour-like pattern and STAT6 nuclear expression: an important diagnostic pitfall

具有孤立性纤维性肿瘤样模式和STAT6核表达的去分化脂肪肉瘤: 一个重要的诊断陷阱

HISTOPATHOLOGY

IF4.1

2023-06-274

OAAI

Shuko Harada

个人简介

教育背景

工作经历

荣誉奖项

研究方向